CompletedNCT07191483

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

Medication studyAges 18–55United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Little Rock and 14 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateStarted: August 27, 2025

Recruitment status: Completed
Enrollment listed in the registry: 149
Sponsor: Kynexis B.V.
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT07191483
Official title: Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Completed

Little Rock · Cerritos · Lemon Grove

12 more locations

FAQ

Who is behind this study?

The study sponsor is Kynexis B.V.

Did this study involve medication?

Yes. The study involved medication, including KYN-5356 low dose, KYN-5356 Medium Dose and KYN-5356 High Dose.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.